Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias

The tumor suppressor TP53 is frequently inactivated in a mutation-independent manner in cancers and is reactivated by inhibiting its negative regulators. We here cotarget MDM2 and the nuclear exporter XPO1 to maximize transcriptional activity of p53. MDM2/XPO1 inhibition accumulated nuclear p53 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Yuki, Ishizawa, Jo, Ayoub, Edward, Montoya, Rafael Heinz, Ostermann, Lauren B., Muftuoglu, Muharrem, Ruvolo, Vivian R, Patsilevas, Tallie, Scruggs, Darah A., Khazaei, Shayaun, Mak, Po Yee, Tao, Wenjing, Carter, Bing Z., Boettcher, Steffen, Ebert, Benjamin L., Daver, Naval G., Konopleva, Marina, Seki, Takahiko, Kojima, Kensuke, Andreeff, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686564/
https://www.ncbi.nlm.nih.gov/pubmed/38019903
http://dx.doi.org/10.1126/sciadv.adh1436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686564/
https://www.ncbi.nlm.nih.gov/pubmed/38019903
http://dx.doi.org/10.1126/sciadv.adh1436

Ejemplares similares